From Nasdaq:

Cathie Wood’s investment strategy focuses on innovation and long-term growth through stocks that are undervalued. Despite declines in the market, Wood’s Ark Innovation fund advanced 67% in 2021, outperforming the S&P 500. She recently added to some of her favorite positions, including CRISPR Therapeutics, Meta Platforms, and Ginkgo Bioworks.

CRISPR Therapeutics, a leader in gene editing, has received authorization for its revolutionary Casgevy product in the U.K. and the U.S. The potential for functional cures and blockbuster revenue is high, with a solid financial situation and a promising pipeline. Despite recent share climbs, the stock is still trading at attractive levels.

Meta Platforms, the parent company of Facebook and other social media giants, has seen a 7% year over year increase in monthly active users, generating over $34 billion in revenue from advertising sales. With a focus on artificial intelligence, the company’s investment in innovation puts it in a strong position for future growth. Despite recent gains, shares are still trading at 22 times forward earnings estimates.

Ginkgo Bioworks is seen as a potential game-changer in the biopharma industry thanks to its groundbreaking approach to engineering cells for a wide array of projects. It has attracted deals with major pharmaceutical companies and saw a 50% increase in revenue from its pharma and biotech programs. With a strong investment in technology, the stock has the potential to skyrocket.



Read more: Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week